ArticleAnnals of translational medicine2022
Gut microbiota diversity in middle-aged and elderly patients with end-stage diabetic kidney disease.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Specific alterations of gut microbiota in diabetic microvascular complications: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Urinary Tract Infection in Patients with Urolithiasis: A Large Retrospective Observational Study of Clinical Features and Microbiological Spectrum.Pathogens (Basel, Switzerland) · 2026Observational
- CD4Frontiers in cellular and infection microbiology · 2026Article
- Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026Review
- Causal effects of gut microbiota on diabetic kidney disease: insights from 16S rRNA sequencing and bidirectional Mendelian randomization.Renal failure · 2025Article
- Gut microbiota and kidney aging: insights into current research.Nutrition & metabolism · 2025Review
- Remodeling of Gut Microbial Networks After Sulforaphane Supplementation in Patients with Chronic Kidney Disease.Life (Basel, Switzerland) · 2025Article
- Beyond Infection: How Antimicrobial Therapies Influence the Urinary Microbiome and Stone Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Therapeutic targeting of PRSS3 to alleviate kidney damage in DKD.Cell biology and toxicology · 2025Article
- An Exploration of the Relationship Between Gut Virome and Cardiovascular Disease: A Comprehensive Review.Reviews in cardiovascular medicine · 2025Review
- The Gut Microbiota Metabolite Butyrate Modulates Acute Stress-Induced Ferroptosis in the Prefrontal Cortex via the Gut-Brain Axis.International journal of molecular sciences · 2025Article
- The gut-kidney axis in chronic kidney disease: mechanisms, microbial metabolites, and microbiome-targeted therapeutics.Frontiers in medicine · 2025Review
- Liuwei Dihuang pills ameliorate renal injury in experimental type 2 diabetes mellitus rat by regulating host-gut microbiota interaction.Frontiers in pharmacology · 2025Article
- Treatment with Gac Fruit Extract and Probiotics Reduces Serum Trimethylamine N-Oxide in Chronic Kidney Disease Rats.Nutrients · 2024Article
- Article
- Integrated Data Mining and Animal Experiments to Investigate the Efficacy and Potential Pharmacological Mechanism of a Traditional Tibetan Functional FoodJournal of inflammation research · 2024Article
- Correlation between gut microbiome and cognitive impairment in patients undergoing peritoneal dialysis.BMC nephrology · 2023Article
- The Dose-Response Effect of Fluoride Exposure on the Gut Microbiome and Its Functional Pathways in Rats.Metabolites · 2023Article
- Exploring the characteristics of gut microbiome in patients of Southern Fujian with hypocitraturia urolithiasis and constructing clinical diagnostic models.International urology and nephrology · 2023Article
- Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease (ESRD), but the mechanism between DKD and ESRD remains unclear. Some experts have put forward the "microbial-centered ESRD development theory", believing that the bacterial load caused by gut microecological imbalance and uremia toxin transfer are the core pathogenic links. The purpose of this study was to analyze the genomic characteristics of gut microbiota in patients with ESRD, specifically DKD or non-diabetic kidney disease (NDKD). Methods: In this cross-sectional study, patients with ESRD were recruited in a community, including 22 DKD patients and 22 NDKD patients matched using gender and age. Fecal samples of patients were collected for 16S rDNA sequencing and gut microbiota analysis. The distribution structure, diversity, and abundance of microflora in DKD patients were analyzed by constructing species evolutionary trees and analyzing alpha diversity, beta diversity, and linear discriminant analysis effect size (LEfSe). Results: The results of our study showed that there were statistically significant differences in the richness and species of gut microbiota at the total level between DKD patients and NDKD patients. The analysis of genus level between the two groups showed significant differences in 16 bacterial genera. Among them, Oscillibacter, Bilophila, UBA1819, Ruminococcaceae UCG-004, Anaerotruncus, Ruminococcaceae, and Ruminococcaceae NK4A214 bacteria in DKD patients were higher than those in NDKD patients. Conclusions: 16S rDNA sequencing technology was used in this study to analyze the characteristics of intestinal flora in ESRD patients with or without diabetes. We found that there was a significant difference in the intestinal flora of ESRD patients caused by DKD and NDKD, suggesting that these may be potential causative bacteria for the development of ERSD in DKD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.